Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spirulina fusiformis is a species of blue-green microalgae (cyanobacteria) that serves as a dense natural source of proteins, carotenoids, and essential micronutrients. It has been clinically investigated for its chemopreventive properties, particularly in the treatment of oral leukoplakia among tobacco chewers. In a landmark study conducted in Kerala, India, daily supplementation with 1 gram of Spirulina fusiformis for twelve months resulted in a significant complete regression of oral lesions compared to placebo, particularly in homogeneous leukoplakia. While it is an effective dietary source of vitamin A precursors, its therapeutic effects in oncology are thought to derive from its complex antioxidant profile rather than a simple increase in serum retinol levels. It is widely available as a nutraceutical and dietary supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spirulina fusiformis.